Join Jeffrey Bradley, MD (Radiation Oncology), Ramaswamy Govindan, MD (Medical Oncology), and Peter Humphrey, MD, PhD (Surgical Pathology) as they present their multidisciplinary expertise on a range of cases pertaining to advanced adenocarcinoma.

Since patients are heterogeneous, patient management should also be individualized. The cases in this webinar are designed to highlight significant clinical decision points concerning treatment selection, toxicity management, and areas of recent change or controversy in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) while reinforcing emerging data from clinical trials. This webinar will allow learners to understand how to apply the standards of care to their practice and healthcare setting.

Most patients with NSCLC have advanced disease (stage IIIB or IV) at diagnosis. Studies show that histology, mutation testing, and other criteria can be used to select the most appropriate systemic therapy for these patients. NSCLC is typically divided into two categories: nonsquamous and squamous cell carcinomas. For nonsquamous, adenocarcinoma is the most common histology. Patients with adenocarcinoma or large cell carcinoma have improved survival when treated with cisplatin and pemetrexed, whereas those with squamous cell carcinoma have improved survival when treated with cisplatin and gemcitabine. Carboplatin/paclitaxel/bevacizumab is another chemotherapy regimen for select patients with advanced NSCLC (i.e., nonsquamous NSCLC, no hemoptysis).

The NCCN Guidelines recommend a multidisciplinary approach for patients with NSCLC so that treatment can be tailored for individual patients, which will improve outcomes by decreasing toxicity, increasing quality of life, and increasing survival. Oncologists need to be aware of the most recent updates about molecular testing and treatment so they can effectively manage their patients with NSCLC.